Low-Dose IL-2 and Hydroxychloroquine Combination for Autoimmune Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS) are inadequate, with existing therapies either having limited efficacy or significant side effects, and there is a need for a combination therapy that effectively inhibits or treats these autoimmune diseases.
Innovation Solution
Administering a therapeutically effective low-dose of interleukin-2 (IL-2) in combination with a disease-modifying antirheumatic drug, such as hydroxychloroquine, to stimulate regulatory T lymphocytes and rebalance the immune system, thereby inhibiting or treating SLE and/or pSS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose IL-2 is administered to treat autoimmune diseases, then T cell proliferation and effector differentiation are enhanced, but the risk of activating effector T cells that mediate disease and aggravating autoimmune conditions increases
Solution Approach 1:
The patent applies parameter changes by administering low-dose IL-2 (0.1-3.5 MIU/day) instead of high-dose IL-2, fundamentally changing the dosage parameter to achieve selective expansion of Treg cells while avoiding activation of pathogenic effector T cells. This dosage optimization resolves the contradiction between therapeutic efficacy and harmful immune activation.
Solution Approach 2:
The patent employs local quality by creating different IL-2 signaling thresholds for different T cell subsets. Treg cells respond to low IL-2 concentrations through high-affinity IL-2Rα, while effector T cells require higher concentrations. This differential response allows selective modulation of immune subsets, expanding Treg cells locally without broadly activating pathogenic cells.
2Reliability
If low-dose IL-2 is administered to expand Treg cells, then immune tolerance is enhanced, but the efficacy and reliability of treatment for autoimmune diseases remains insufficient when used alone
Solution Approach 1:
The patent merges low-dose IL-2 therapy with hydroxychloroquine treatment to achieve synergistic effects. IL-2 selectively expands Treg cells while hydroxychloroquine provides broad immunomodulation and anti-inflammatory activity. This combination therapy resolves the limitation of insufficient efficacy by integrating two complementary mechanisms of action.
Solution Approach 2:
The patent creates a composite therapeutic regimen combining two distinct therapeutic agents with different mechanisms of action. The IL-2/hydroxychloroquine combination functions as a composite treatment strategy, where each component contributes unique immunomodulatory properties that together achieve superior therapeutic outcomes compared to either agent alone.
3Ease of operation
If existing therapies for SLE and pSS are used, then treatment is provided, but the therapies have limited efficacy or significant side effects
Solution Approach 1:
The patent converts the harmful overactivation of effector T cells into a beneficial expansion of Treg cells by using low-dose IL-2. Instead of suppressing the immune system broadly with high-dose immunosuppressants that cause significant side effects, the therapy selectively redirects immune activity toward tolerance-inducing Treg cells, transforming potential harm into therapeutic benefit while minimizing adverse effects.
Data Source
AI summary
A method of inhibiting or treating systemic lupus erythematosus (SLE) and/or primary Sjögren's Syndrome (pSS) in a subject in need thereof is disclosed. The method calls for administering to the subject a therapeutically effective low-dose amount of interleukin-2 and hydroxychloroquine alone or in combination with a therapeutically effective amount of another disease-modifying antirheumatic drug. That combination results in inhibiting or treating SLE and/or pSS in the subject.